For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenues | - | 0 | - | - |
| Research and development | - | 423,277 | 2,762,709 | 7,136,679 |
| General and administrative | 527,902 | 919,488 | 1,695,550 | 1,367,169 |
| Asset impairment loss | - | 402,746 | - | - |
| Total operating expenses | 527,902 | 1,745,511 | 4,458,259 | 8,503,848 |
| Loss from operations | -527,902 | -1,745,511 | -4,458,259 | -8,503,848 |
| Interest income (expense) | 8,116 | 4,866 | -474,570 | 49,536 |
| Inducement expense | - | 0 | - | - |
| Change in fair value of contingent consideration and derivative financial instruments | 47,280 | 698,073 | 66,881 | 4,529,100 |
| Loss before income taxes | -472,506 | -1,042,572 | -4,865,948 | -3,925,212 |
| Income tax benefit | - | 0 | - | - |
| Net loss | -472,506 | -1,042,572 | -4,865,948 | -3,925,212 |
| Basic | -0.04 | -0.09 | -0.72 | -0.68 |
| Basic | 11,620,317 | 11,328,122 | 6,718,962 | 5,799,126 |
| Diluted | -0.04 | -0.09 | -0.72 | -0.68 |
| Diluted | 11,620,317 | 11,328,122 | 6,718,962 | 5,799,126 |
Hepion Pharmaceuticals, Inc. (CTRVP)
Hepion Pharmaceuticals, Inc. (CTRVP)